Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,502 | 1,124 | 3,148 | 12,265 | 194 |
| Receivables | 124 | 98 | 277 | 442 | N/A |
| Other current assets | 0 | 0 | 27 | 25 | 24 |
| TOTAL | $5,345 | $2,289 | $5,299 | $15,663 | $348 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 253 | 419 | 586 | 755 | 4 |
| TOTAL | $253 | $419 | $586 | $755 | $4 |
| Total Assets | $5,597 | $2,708 | $5,885 | $16,417 | $352 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 670 |
| Accounts payable and accrued liabilities | 1,357 | 1,936 | 2,944 | 301 | 1,725 |
| Accrued Expenses | 549 | 542 | 2,227 | 3,408 | 345 |
| TOTAL | $2,207 | $3,333 | $9,464 | $16,482 | $7,010 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | 140 | 4,441 | N/A |
| Other Non-Current Liabilities | 10 | 40 | 346 | 3,715 | 218 |
| TOTAL | $10 | $26 | $451 | $8,094 | $N/A |
| Total Liabilities | $2,217 | $3,359 | $9,915 | $24,575 | $7,010 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,405 | 489 | 86 | 8 | 2 |
| Common Shares | 0 | 0 | 0 | 0 | 2 |
| Retained earnings | -129,544 | -121,557 | -110,931 | -85,846 | -55,959 |
| Other shareholders' equity | -329 | -328 | -315 | -280 | -218 |
| TOTAL | $3,380 | $-651 | $-4,030 | $-8,158 | $-6,658 |
| Total Liabilities And Equity | $5,597 | $2,708 | $5,885 | $16,417 | $352 |